Baxter International stock
Price history
+45.75% over the period1 year: from $17.42 (November 20, 2025) to $25.39 (November 20, 2026), +45.75%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | $25.39 |
| October 30, 2026 | $23.00 |
| September 30, 2026 | $24.00 |
| August 31, 2026 | $26.00 |
| July 31, 2026 | $26.16 |
| June 30, 2026 | $21.32 |
| May 29, 2026 | $18.78 |
| April 30, 2026 | $17.58 |
| March 31, 2026 | $16.80 |
| February 27, 2026 | $20.37 |
| January 30, 2026 | $20.07 |
| December 31, 2025 | $19.11 |
| November 28, 2025 | $18.74 |
| November 20, 2025 | $17.42 |
At a glance
The company
Provides sterile IV solutions, infusion systems, parenteral nutrition, anesthetics, surgical equipment, patient monitoring technologies and respiratory health devices for hospitals and home care
Latest results
Quarter to September 30, 2026 · EPS $0.58 (estimate $0.52)
Dividend
TickerLandia's take on Baxter International
- Strong point: Market momentum (83/100 in its group). Weak point: Earnings stability (4/100).
- “Value traps” (United States): No. 5 of 7.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−15.37% from the 52-week high
Analysts · 15 analysts
Average target$27.25+7.33% vs. price
Buy 2 · Hold 12 · Sell 1 · Hold
TickerLandia Fingerprint: Baxter International
Compared with similar companies: very low earnings stability, very low profitability, and very low price.
Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 888 North American stocks.
Pricevery low13
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 10.9 19 Price/book 2.02 19 Forward P/E 12.4 7 Price/sales 1.13 7 Profitabilityvery low13
How much it earns on revenue and capital.
Metric Value Position in group ROA 2.7% 16 Operating margin 7.6% 19 Gross margin 33.4% 13 Net margin −6.2% 7 ROE −9.0% 7 Earnings stabilityvery low4
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 15.4% 4 Loss-making yearscounts in reverse: lower means more earnings stability 3 of 5 annual reports 3 Growthlow37
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +5.00% 43 Average revenue growth (3 years) +3.79% 31 Financial strengthlow22
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 1.36 11 Current ratio 1.79 49 Interest coverage 3.58 22 Net debt/EBITDAcounts in reverse: lower means more financial strength 3.87 8 Dividendhigh63
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 0.2% 2 Payout ratiopays out more than its earnings 154.7% 94 Consecutive dividend years at least 37 years 94 Market momentumvery strong83
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +6.30% 58 Relative strength (6 months) +45.50% 93 1-year return +45.75% 91 Distance from 200-day average +16.64% 91 Riskaverage54
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 29.1% 49 Volatility (60 days) 35.3% 50 Beta (1 year) 1.00 64
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Baxter International is cheaper than similar companies
Baxter International's Forward P/E: 12.4, −26% against the median of a group of 11 similar companies (16.7).
Compared with 11 similar companies
| Metric | Baxter International | Position in the group | Band |
|---|---|---|---|
| Forward P/E | 12.4 | Low | |
| Operating margin | 7.6% | Low | |
| ROE | -9.0% | Low | |
| Debt/equity | 1.36 | High | |
| Price/book | 2.02 | Low |
Grey band: the middle half of the group; tick: the median; dot: Baxter International. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$2.98B
Latest quarter · Q3 2026
Net income
$294M
Latest quarter · Q3 2026
Quarterly net margin
9.9%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $13.14B
- EPS
- -$1.21
- Volume
- 4.32M
- Daily trading
- €160.77M
- Dividend yield
- 0.16%
How Baxter International is changing
All resultsRevenue fell 0.7% a year on average over the last 5 years
Operating margin rose from −28.3% to −2.7%
Revenue has grown for 3 fiscal years in a row
Returns
Baxter International returns with dividends
$1,000 invested in Baxter International 5 years ago, on November 22, 2021, would be worth $353 today with dividends reinvested: −64.66% in total, −18.80% per year. On price alone it would be $320 (−67.96%).
| Period | Baxter International | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +3.59% | −10.40% | $1,036 |
| 6 months | +35.27% | −7.03% | $1,353 |
| Year to date | +32.86% | +0.95% | $1,329 |
| 1 year | +46.03% | +5.68% | $1,460 |
| 3 years | −24.66% | +51.96% | $753 |
| 5 years | −64.66% | +47.57% | $353 |
| 10 years | −37.08% | +214.37% | $629 |
Over the last 6 months it has done better than 84% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Baxter International: technical analysis
Baxter International is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 73.0% below its highest close since January 2, 1990 ($94.14, April 20, 2020).
- Trend
- Upward
- RSI (14 sessions)
- 50
- Between 30 and 70
- vs 200-session average
- +16.64%
Support and resistance
Price areas where Baxter International has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$25.87+1.89%2 touches, last on October 16, 2026
- Last price$25.39
- Support$23.62−6.97%3 touches, last on October 20, 2026
- Support$22.49−11.42%3 touches, last on October 30, 2026
- Support$21.28−16.20%4 touches, last on July 23, 2026
Volatility and risk
Over the last year it has moved roughly in line with the S&P 500.
- Beta (1 year) vs S&P 500
- 1.00
- Volatility (60 sessions, annualised)
- 35.3%
- Largest fall in the last year
- −29.05%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Baxter International: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Baxter International has been November: +2.58% on average, positive in 24 years out of 36. The weakest has been October: −2.86% on average, positive in 15 years out of 37.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +2.54% | +1.73% | 21 of 36 |
| February | +0.20% | +0.70% | 20 of 37 |
| March | +0.21% | +1.53% | 22 of 37 |
| April | +0.97% | +1.10% | 21 of 37 |
| May | +1.02% | +0.66% | 22 of 37 |
| June | +0.55% | +0.54% | 20 of 37 |
| July | +2.23% | +5.44% | 24 of 37 |
| August | +0.11% | +0.80% | 21 of 37 |
| September | −1.58% | −0.55% | 18 of 37 |
| October | −2.86% | −2.27% | 15 of 37 |
| November | +2.58% | +2.50% | 24 of 36 |
| December | +1.11% | +1.32% | 22 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Baxter International and its competitors
Sterile intravenous solutions, infusion systems and parenteral nutrition therapies are among the products hospitals and patients associate with Baxter. The company also makes surgical hemostat and sealant products, smart bed systems, patient monitoring devices, inhaled anesthetics and generic injectable pharmaceuticals, organized in three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. Its products reach hospitals, nursing homes, dialysis centers, ambulatory surgery centers and patients at home, sold through a direct sales force, independent distributors and drug wholesalers.
- Headquarters
- Deerfield, United States
- Employees
- 37,500
- Founded
- 1931
- Chief executive
- Andrew Hider
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Baxter InternationalBAX | $13.14B | 7.6% | — | +35.27% |
| SolventumSOLV | $14.36B | 5.9% | 94.9 | +10.99% |
| Cooper CompaniesCOO | $11.2B | 12.9% | 20.2 | −4.65% |
| Align TechnologyALGN | $10.94B | 19.6% | 22.6 | −5.03% |
| RepligenRGEN | $10.89B | 8.1% | — | +46.60% |
| AvantorAVTR | $10.06B | 8.0% | 29.7 | +88.32% |
Same industry or related industries, similar size. Compare Baxter International with its competitors · Full profile
More on Baxter International
- Baxter International revenue and financials
- Baxter International dividend and valuation
- Baxter International stock return
- Baxter International employees, headquarters and business
